Alto Neuroscience reported a net loss of $79.0 million for the nine months ended September 30, 2026, compared to $47.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a private placement and direct shelf offering, ending the period with $319.3 million in cash and cash equivalents.
Alto Neuroscience reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $319.8 million following a $100 million financing. The company confirmed its clinical pipeline remains on track, with topline data for its PACE-1 trial in treatment-resistant depression expected in the second half of 2027.
“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027. PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.”
Amit Etkin, M.D., Ph.D., founder and chief executive officer
Alto Neuroscience President and CFO Nicholas Conrad Smith Sells $3.57M of Stock
Nicholas Conrad Smith, President and CFO, sold 134,886 shares of Alto Neuroscience, Inc. at $25.78 to $26.87 a share (average $26.45) in 3 transactions, worth $3.57M in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 24,060 (-3.6%).